Assessment of Transcultural Psychotherapy in Child Major Depressive Disorder (EDPT-ADOS)

March 12, 2020 updated by: Assistance Publique - Hôpitaux de Paris

Assessment of Transcultural Psychotherapy to Treat Major Depressive Disorder in Children and Adolescents From Migrant Families: a Bayesian Randomized Controlled Trial

The symptomatic and clinical expression of psychiatric disorders in children and adolescents is strongly influenced by the cultural setting they are growing up in. These cultural variations complicate psychiatric care, especially for migrant children, for whom appropriate care must be designed.

Transcultural psychotherapy is an original psychotherapeutic technique developed to meet these specific requirements in France and in different European and American countries. Its theoretical and methodological foundations rest on the works of George Devereux in ethnopsychiatry (1970). A psychotherapeutic technique intended for first-generation migrants was developed by Tobie Nathan and coll (1986). Marie-Rose Moro and colleagues (1990) have adapted this technique to second-generation migrants.

Indicated as a second-line treatment after the failure of standard management, this technique is fully formalized today. It comprises group consultations for the child and the family as a one-hour session each month, directed by a principal therapist, assisted by a group of co-therapists (of diverse cultural origins and occupations) and an interpreter in the family's mother tongue. The concept of culture is used to establish the therapeutic alliance, decode the symptoms, and propose treatment.

The children and adolescents receiving this treatment have varied psychopathological profiles, mostly involving depressive and/or anxiety disorders. Specifically, migrants' children are especially vulnerable to depression, their psychiatric care is generally longer and less effective than in the general population, and their rate of treatment failure higher.

Transcultural psychotherapy has demonstrated its value in these situations in numerous qualitative studies, but its efficacy has not yet been assessed by a method providing a high level of evidence, such as randomized controlled trials.

Study Overview

Status

Not yet recruiting

Detailed Description

Mixed method study using a multicenter, Bayesian randomized clinical trial with blinded evaluation of the primary outcome. Two parallel groups of 40 children or adolescents from 6 to 20 years-old and their family will be included. In the experimental group, patients will attend six sessions of transcultural therapy in addition to usual care. The improved Clinical Global Impression scale scores at 6 months will be compared across groups. Qualitative analysis of families and therapists' interviews will allow to specify the therapeutic processes and acceptability of the therapy.

Study Type

Interventional

Enrollment (Anticipated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Bobigny, France
        • Service de Psychopathologie de l'enfant, de l'adolescent, CHU Avicenne
        • Contact:
      • Bordeaux, France
        • Service de médecine interne, unité de consultation transculturelle, CHRU Saint-André (CHU Bordeaux)
        • Contact:
      • Clermont-Ferrand, France
        • Service de psychiatrie de l'enfant et de l'adolescent, CHRU Gabriel Montpied
        • Contact:
      • Paris, France, 75000
      • Paris, France
        • Secteur 75G23, Centre Médico-psychologique (CMP), GHU PARIS, Maison blanche
        • Contact:
      • Toulouse, France
        • Centre Médico-psychologique, Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Hôpital La Grave, CHU Toulouse
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 20 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Be a child aged or an adolescent aged 6-20 years-old (this may be a declaratory age at the time of the consultation or based on a document for a residence request if no other identity documents are available)
  • Be a first or second-generation migrant (born abroad or born from at least one parent who is born abroad)
  • Have a psychological and/or psychiatric follow-up by a first-line care
  • Have been referred for transcultural psychotherapy by their first line care to treat depression resistant to standard management.
  • Present a depression according to the clinician who proposes the transcultural treatment (first line therapist), based on usual as well as cultural symptoms criteria of the below list:

    • Sadness
    • Diminish interest or pleasure in most of the usual activities
    • Insomnia or hypersomnia
    • Psychomotor agitation
    • Asthenia, loss of energy
    • Feeling of worthlessness or excessive guilt
    • Recurrent throughs of death
    • School problems (school failure, drop in grades, aggressivity with adult, school refusal…)
    • Mutism, and selective mutism
    • Runaways
    • Aggressivity
    • Impulsivity
    • Violence and delinquency
    • Conflicts with parents and adults from the community
    • Exclusion from family
    • Somatic pains
    • Massive separation anxiety
    • Regressive symptoms - loosing of an already acquired function such as speech, walk, stay alone for a sufficient time in relation to age, manage stress or anxiety for reasonable situations…
    • Denial of medical care for a chronic disease with no evident reasons
    • Cultural designation such as possessed by a spirit, being a child witch, or other cultural designations
    • State of trance The list is not exhaustive, and some other symptoms may be accepted if the first line clinician as well as the referent agree. The patients will be well characterized after inclusion.
  • Present a score >= 4 on the iCGI - Severity at inclusion.
  • Present transcultural issues confirmed by the referent (usual procedure of indirect pre-selection based on the presentation of the situation by referring physician)
  • Have an informed consent signed by both parents/ one parent / tutor / adult patient (cf. 14.1 paragraph)

Exclusion Criteria:

  • Patient or family has previously had transcultural psychotherapy
  • Patient presents an acute psychiatric disorder which hinders the realization of the transcultural therapy - for example, excited delirium with great psychic disorganization, or high suicidal risk patients. These situations will be excluded during the screening time based on the first line therapist evaluation
  • Patient presents an acute somatic disease which may hinder the well organization of the therapy
  • Patient addressed for a legal expertise
  • Child's/Adolescent's refusal
  • Pregnant or breastfeeding (for women for young women of childbearing age)
  • Participation in another interventional study
  • Patient under guardianship or curatorship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Transcultural psychotherapy
In addition to usual care, the participants in the treatment group receive transcultural psychotherapy in the inclusion centers, which consists of 5 sessions every 7 weeks (W6, W13, W20, W27, and W34). During all the research process, participants from both groups continue their usual care provided by the referent medical team outside the inclusion center.
In addition to usual care, the participants receive transcultural psychotherapy
No Intervention: standard care
usual care provided by the referent medical team

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severity Score on the Improved Global Impression Scale (iCGI) to assess remission
Time Frame: at week 34 visit (v5)

.iCGI score is a scale ranging from 1 to 7, 1 being Normal, not at all ill, and 7 - Among the most extremely ill patients.

  1. - Normal, not at all ill
  2. - Borderline mentally ill
  3. - Mildly ill
  4. - Moderately ill
  5. - Markedly ill
  6. - Severely ill
  7. - Among the most extremely ill patients

Remission is defined as a mean iCGI score over the 3 experts <4 at 28 weeks of treatment (W34).

at week 34 visit (v5)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severity score on the iCGI
Time Frame: at baseline and weeks 6, 13, 20, 27 and 34 and 52
To compare the course of the severity of depression in each group over the first 34 weeks after inclusion
at baseline and weeks 6, 13, 20, 27 and 34 and 52
Score on the French version of the Children's Depression Rating Scale-Revised (CDRS-R)
Time Frame: at baseline and weeks 6, 13, 20, 27 and 34 and 52

It's a 17-item scale with answers on 5 or 7-point Likert scale (total score ranges from 17 to 113). A score ≥ 40 is indicative of depression, whereas a score ≤28 is often used to define remission.

To compare the course of the level of depressive symptoms in each group over the first 34 weeks after inclusion

at baseline and weeks 6, 13, 20, 27 and 34 and 52
Score on the French version of the State-Trait Anxiety Inventory for children (STAI-C)
Time Frame: at baseline and weeks 6, 13, 20, 27 and 34 and 52
To compare the course of the level of anxiety symptoms in each group over the first 34 weeks after inclusion
at baseline and weeks 6, 13, 20, 27 and 34 and 52
Score changes in Depression and anxiety Scores between Week 34 and week 52
Time Frame: at 34 and 52 weeks
To evaluate the persistence of the efficacy of transcultural psychiatry over time by describing the course of the severity of the depression and of the depressive and anxiety symptoms from 34 to 52 weeks after inclusion in the group of patients treated by transcultural psychotherapy during the first 34 weeks
at 34 and 52 weeks
analysis of the content of the clinical data collected during the visits
Time Frame: between 34 and 44 weeks
To describe the therapeutic processes that enabled the improvement of patients treated by transcultural psychotherapy
between 34 and 44 weeks
analysis of the content of the interview with the families and therapists at the end of the treatment
Time Frame: between 34 and 44 weeks
For this secondary objective concerning the group of patients treated by transcultural psychotherapy, a qualitative design will be used to explore the perceived efficacity and acceptability of the therapy. Investigators will organize two semi-structured interviews after the fifth therapy session. These semi-structured interviews will be conducted by a psychologist trained in transcultural care. One interview will concern the family and will explore, with the help of an interpreter speaking the native language of the family, the acceptability of the care as well as success factors identified by the family. The other interview will concern the therapists and will explore the success factors identified by the professionals. The interviews guides have been constructed by specialists of transcultural care in childhood and adolescence To describe the perceived efficacy and acceptability of the transcultural psychotherapy for the patient and the family
between 34 and 44 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jonathan LACHAL, PhD, Assistance Publique - Hôpitaux de Paris

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

April 1, 2020

Primary Completion (Anticipated)

October 1, 2022

Study Completion (Anticipated)

October 1, 2023

Study Registration Dates

First Submitted

December 16, 2019

First Submitted That Met QC Criteria

December 18, 2019

First Posted (Actual)

December 20, 2019

Study Record Updates

Last Update Posted (Actual)

March 16, 2020

Last Update Submitted That Met QC Criteria

March 12, 2020

Last Verified

December 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Major Depressive Disorder

Clinical Trials on Transcultural psychotherapy

3
Subscribe